Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Krop

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Molecular Cancer Research : MCR|September 24, 2004
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor typesIan Krop, Audrey Player, Ana Tablante, et al.
Journal of the National Cancer Institute|February 18, 2015
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancerAna M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Breast Cancer Research and Treatment|April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)Jennifer R Bellon, Hao Guo, William T Barry, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Clinical Breast Cancer|May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer SymposiumKomal Jhaveri, Carey K Anders, Aditya Bardia, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
JCO Clinical Cancer Informatics|January 9, 2026
Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical TrialsGuannan Gong, Jessica Liu, Sameer Pandya, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Molecular Cancer Research : MCR|September 24, 2004
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor typesIan Krop, Audrey Player, Ana Tablante, et al.
Journal of the National Cancer Institute|February 18, 2015
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancerAna M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Breast Cancer Research and Treatment|April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)Jennifer R Bellon, Hao Guo, William T Barry, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Clinical Breast Cancer|May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer SymposiumKomal Jhaveri, Carey K Anders, Aditya Bardia, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
JCO Clinical Cancer Informatics|January 9, 2026
Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical TrialsGuannan Gong, Jessica Liu, Sameer Pandya, et al.
Pageof 7